TransCode Therapeutics, Inc. Announces Results of Special Meeting
TransCode Therapeutics, Inc. (RNAZ)
Company Research
Source: PR Newswire
BOSTON, Feb. 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today held the adjourned session of its Special Meeting from February 4, 2025, (the "Special Meeting"). Shareholders voted upon the two proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission (the "SEC") on December 30, 2024 (the "Special Meeting Proxy Statement").The presence, by remote communication or by proxy, of the holders of at least one-third of the outstanding shares of capital stock entitled to vote at the m
Read more
Impact Snapshot
Event Time:
RNAZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAZ alerts
High impacting TransCode Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAZ
News
- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical TrialPR Newswire
- TransCode Therapeutics, Inc. Announces Results of Special Meeting [Yahoo! Finance]Yahoo! Finance
- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical TrialPR Newswire
RNAZ
Sec Filings
- 2/25/25 - Form 8-K
- 2/14/25 - Form SCHEDULE
- 2/4/25 - Form DEFA14A
- RNAZ's page on the SEC website